MIV-247

MIV-247 is a selective cathepsin S inhibitor with Kis of 2.1, 4.2 and 7.5 nM for human, mouse and cynomolgus monkey cathepsin S, respectively.

Signaling Pathways >> Metabolic Enzyme/Protease >> Cathepsin

Research Areas >> Neurological Disease

IC50: 2.1 nM (Human Cathepsin S), 4.2 nM (Mouse Cathepsin S), 7.5 nM (Cynomolgus monkey Cathepsin S)[1]

Oral administration of MIV-247 (100-200 µmol/kg) dose-dependently attenuates mechanical allodynia by up to approximately 50% reversal when given as a single dose or when given twice daily for 5 days. Cathepsin S inhibition with MIV-247 exerts significant antiallodynic efficacy alone, and also enhances the effect of gabapentin and pregabalin without increasing side effects or inducing pharmacokinetic interactions[1].

Mice[1] MIV-247 is administered via oral gavage to Male C57BL/6 mice (20-30 g) at a dose volume of 5 ml/kg at doses up to 200 µmol/kg. In the PK studies, seven blood samples (20 µL) are drawn from the lateral saphenous vein of each mouse at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 5 hours, and 7 hours postdose[1].

[1]. Hewitt E. et al. Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):387-96.

Leupeptin hemisulfate salt | E-64 | PMSF | CA-074 methyl ester | LY 3000328 | Odanacatib(MK-0822) | CA 074 TFA | VBY-825 | Balicatib | Cysteine Protease inhibitor | Papain | MK-0822 | Cathepsin Inhibitor 2 | E-64c